BUZZ-Kyverna Therapeutics falls on $100 mln stock sale plans
I'm PortAI, I can summarize articles.
Kyverna Therapeutics' shares fell 6.9% to $10.08 in extended trading after announcing a $100 million stock sale. Despite this, the stock had surged 23.2% to $10.82 after positive results from a mid-stage study of its cell therapy, miv-cel. The company has a market cap of approximately $475 million with 43.8 million shares outstanding. Analysts remain bullish with a median price target of $29, up from $22.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments